Akoya BioSciences AKYA

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.03 (+2.24%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Akoya BioSciences (AKYA)
    Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.59

    • Market Cap

      $78.82 Million

    • Price-Earnings Ratio

      -7.57

    • Total Outstanding Shares

      49.57 Million Shares

    • Total Employees

      330

    • Dividend

      No dividend

    • IPO Date

      April 16, 2021

    • SIC Description

      Laboratory Analytical Instruments

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      100 campus drive, Marlborough, MA, 01762

    • Homepage

      https://www.akoyabio.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities, Continuing$-150,000
    Net Cash Flow, Continuing$3.61 Million
    Net Cash Flow From Operating Activities, Continuing$-9.26 Million
    Net Cash Flow From Investing Activities, Continuing$13.02 Million
    Net Cash Flow From Investing Activities$13.02 Million
    Net Cash Flow$3.61 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Income Tax Expense/Benefit$44,000
    Income/Loss From Continuing Operations After Tax$-10.53 Million
    Benefits Costs and Expenses$29.30 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Selling, General, and Administrative Expenses$14.67 Million
    Diluted Average Shares$49.50 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-10.51 Million
    Other Comprehensive Income/Loss Attributable To Parent$20,000
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$-10.51 Million
    Comprehensive Income/Loss$-10.51 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Long-term Debt$75.90 Million
    Wages$4.26 Million
    Cash$39.30 Million
    Equity Attributable To Parent$13.63 Million
    Other Non-current Liabilities$12.45 Million
    Accounts Payable$8.76 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AKYA from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.